» Articles » PMID: 32636756

Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin

Overview
Journal Front Physiol
Date 2020 Jul 9
PMID 32636756
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

A large number of systemically administered drugs have the potential to cause drug-induced interstitial lung disease (DIILD). We aim to characterize a model of DIILD in the rat and develop imaging biomarkers (IBs) for detection and quantification of DIILD. In this study, Sprague-Dawley rats received one single dose of intratracheal (i.t.) bleomycin and were longitudinally imaged at day 0, 3, 7, 14, 21, and 28 post dosing, applying the imaging techniques magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Bronchoalveolar lavage fluid (BALF) was analyzed for total protein and inflammatory cells. Lungs were saved for further evaluation by gene analysis using quantitative-PCR and by histology. Lung sections were stained with Masson's-Trichrome staining and evaluated by modified Ashcroft score. Gene expression profiling of inflammatory and fibrotic markers was performed on lung tissue homogenates. Bleomycin induced significant increase in total protein concentration and total cell count in bronchoalveolar lavage (BAL), peaking at day 3 ( > 0.001) and day 7 ( > 0.001) compared to control, respectively. Lesions measured by MRI and PET signal in the lungs of bleomycin challenged rats were significantly increased during days 3-14, peaking at day 7. Two subgroups of animals were identified as low- and high-responders by their different change in total lung volume. Both groups showed signs of inflammation initially, while at later time points, the low-responder group recovered toward control, and the high-responder group showed sustained lung volume increase, and significant increase of lesion volume ( < 0.001) compared to control. Lastly, important inflammatory and pro-fibrotic markers were assessed from lung tissue, linking observed imaging pathological changes to gene expression patterns. In conclusion, bleomycin-induced lung injury is an adequate animal model for DIILD studies and for translational lung injury assessment by MRI and PET imaging. The scenario comprised disease responses, with different fractions of inflammation and fibrosis. Thereby, this study improved the understanding of imaging and biological biomarkers in DIILD and lung injury.

Citing Articles

Human fetal lung mesenchymal stem cells ameliorate lung injury in an animal model.

Golmohammadi M, Sheikhha M, Ganji F, Shirani A, Barati M, Kalantar S Sci Rep. 2025; 15(1):6433.

PMID: 39984612 PMC: 11845704. DOI: 10.1038/s41598-025-91406-0.


Utilizing MRI, [F]FDG-PET and [Zr]Zr-DFO-28H1 FAP-PET tracer to assess inflammation and fibrogenesis in a reproducible lung injury rat model: a multimodal imaging study.

Boswinkel M, Raave R, Veltien A, Scheenen T, Fransen Petterson N, In t Zandt R Front Nucl Med. 2024; 3:1306251.

PMID: 39355041 PMC: 11440995. DOI: 10.3389/fnume.2023.1306251.


Contrast enhanced longitudinal changes observed in an experimental bleomycin-induced lung fibrosis rat model by radial DCE-MRI at 9.4T.

In t Zandt R, Mahmutovic Persson I, Tibiletti M, von Wachenfeldt K, Parker G, Olsson L PLoS One. 2024; 19(9):e0310643.

PMID: 39331604 PMC: 11432896. DOI: 10.1371/journal.pone.0310643.


MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycin.

Mahmutovic Persson I, Fransen Petterson N, Liu J, In t Zandt R, Carvalho C, Orbom A Front Med (Lausanne). 2024; 11:1276420.

PMID: 38654839 PMC: 11035813. DOI: 10.3389/fmed.2024.1276420.


Early Detection and Staging of Lung Fibrosis Enabled by Collagen-Targeted MRI Protein Contrast Agent.

Ibhagui O, Li D, Han H, Peng G, Meister M, Gui Z Chem Biomed Imaging. 2023; 1(3):268-285.

PMID: 37388961 PMC: 10302889. DOI: 10.1021/cbmi.3c00023.


References
1.
Huaux F, Liu T, McGarry B, Ullenbruch M, Phan S . Dual roles of IL-4 in lung injury and fibrosis. J Immunol. 2003; 170(4):2083-92. DOI: 10.4049/jimmunol.170.4.2083. View

2.
Bondue B, Castiaux A, Van Simaeys G, Mathey C, Sherer F, Egrise D . Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients. Respir Res. 2019; 20(1):10. PMC: 6334423. DOI: 10.1186/s12931-019-0974-5. View

3.
Wang X, Zhang Y, Kim H, Zhou Z, Feghali-Bostwick C, Liu F . Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006; 203(13):2895-906. PMC: 1850940. DOI: 10.1084/jem.20061536. View

4.
Hubner R, Gitter W, Mokhtari N, Mathiak M, Both M, Bolte H . Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008; 44(4):507-11, 514-7. DOI: 10.2144/000112729. View

5.
Tournebize R, Doan B, Dillies M, Maurin S, Beloeil J, Sansonetti P . Magnetic resonance imaging of Klebsiella pneumoniae-induced pneumonia in mice. Cell Microbiol. 2005; 8(1):33-43. DOI: 10.1111/j.1462-5822.2005.00597.x. View